COVID-19 是与SARS 和MERS 结构相似的冠状病毒，全基因组序列上与SARS 有79%左右的相似性，且感染路径形同，因此COVID-19 可借鉴之前SARS 和MERS的疫苗开发经验，在动物模型、抗原位点、佐剂等的选择上优化，并结合新的技术开发疫苗，优选出促进T 细胞免疫和中和抗体产生的疫苗，达到最优免疫效果。

为什么海外疫苗集中程度如此之高，很多人倾向于从进入壁垒高，以及从疫苗市场规模小、回报率低，企业进入疫苗领域积极性不高来解释。我们认为仅以上不能很好的解释海外疫苗市场的高集中程度。疫苗市场区别于其他药品的最大特点是政府参与度远高其他制药领域，我们认为欧美政府在疫苗准入和采购上发挥着重要作用，政府行为很大程度上影响了海外疫苗市场的供给结构。

5 月9 日，京津冀及黑吉辽蒙晋鲁（“3+6”联盟）完成人工晶体类高值耗材联合带量采购信息申报并公示竞争方式拟中选结果，国家医保局局长胡静林出席申报信息公开大会。

行情回顾：过去一周A 股医药股板块指数上涨2.97%，上证综指上涨1.23%，深证成指上涨2.61%，创业板指上涨2.70%。

2020 年4 月，中检所共批签发疫苗5,479.40 万瓶，同比增长37.36%，环比增长20.01%。2020 年1-4 月，累计批签发疫苗18,696 万瓶，同比增长26.71%。

在上2 篇报告《新冠病毒疫苗离我们有多远？》、《mRNA 疫苗究竟是“何方神圣”？》我们分别对新型冠状病毒疫苗研发概况、mRNA 疫苗进行梳理。这是我们的新冠病毒疫苗系列报告的第3 篇，自新冠病毒疫情爆发以来海内外加速推进疫苗研发，截止目前已有7 个企业参与/合作的新冠病毒候选疫苗进入临床试验，此文我们主要和大家聊聊，新冠病毒疫苗是怎么设计并开展临床试验？

Migraine is a common neurological disease characterized by recurrent attacks of severe head pain. Often unilateral, the headaches can last from four hours to three days. Pain is often associated with other symptoms, such as nausea, vomiting, increased sensitivity to light, increased sensitivity to sound, sweating, and diarrhea. An increasing prevalence of migraine has been reported in women than men. However, it often remains undiagnosed and untreated. Despite improvements in the industry, migraine is still found to remain undiagnosed in at least 50% of patients, and less than 50% of migraine patients consult a physician. The majority of the drugs currently available are approved for the acute form of the condition, led by generic triptans as the first-line treatment. NSAIDs are the commonly used drugs for patients with migraine frequently used NSAIDs for migraine and is effective in treating acute migraine headache. Triptans also effectively relieve the pain associated with migraines.

Laser is an acronym used for light amplification by stimulated emission of radiation, which has a specific wavelength and creates high-intensity light. Medical lasers are devices that are used for the treatment of various diseases, such as eye-related diseases, cardiology-related diseases, urology diseases, and tissue removal leading to increased adoption of lasers for diverse medical application, including ophthalmology, dermatology, urology, and cardiovascular. The market revenue includes revenue generated from the devices used for the therapy and excludes the revenue generated from medical lasers used for diagnosis purpose and the services provided by the manufacturers of medical lasers. The market is experiencing a significant growth owing to factors such as high prevalence of eye-related diseases, cardiology issues, neurological issues, and urology related health conditions.

The rising adoption of various healthcare IT systems in hospitals and the explosion of healthcare data are major factors expected to supplement the growth of the market. Electronic data is a rapidly-emerging topic in the healthcare IT market. Since its inception, the healthcare industry has generated large amounts of data, driven by record keeping, compliance and regulatory requirements, and patient care. Thus, there is a huge need for efficient medical document management systems in the market. Furthermore, there are various small and big market players present in the market and the majority of them are focusing on providing interoperability in their systems. Besides, there are few systems which provide integrated solutions that come along with systems like EHR, etc.

The report provides market dynamics and trends related to the global irritable bowel syndrome treatment market. In addition, it presents the estimations and forecast of the market. The study estimates the revenue generated from the sales of irritable bowel syndrome treatment drugs; however, it excludes the irritable bowel syndrome treatment service revenue. The valuations comprise revenue generated from irritable bowel syndrome treatment drug type such as rifaximin, eluxadoline, lubiprostone, linaclotide, and others that are used for the treatment of irritable bowel syndrome. Furthermore, the report excludes revenue generated from post- sale services of irritable bowel syndrome treatment drugs.